

Anacor Pharmaceuticals, Inc.
Form SC 13D/A
February 13, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

ANACOR PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, \$0.001 Par Value

(Title of Class of Securities)

032420 101

(CUSIP Number)

Victoria A. Whyte

GlaxoSmithKline plc

980 Great West Road

Brentford, Middlesex TW8 9GS

Telephone: +44 (0)208 047 5000

Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

October 30, 2014

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 032420

101
13D/A2
of 7

SCHEDULE
Page 2

1. Names of Reporting Persons.

GlaxoSmithKline plc

2. Check the Appropriate Box if a Member of a Group

(a)
(b)

3. SEC Use Only
4. Source of Funds

WC

5. Check if Disclosure of Legal Proceedings Is Required
Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

England and Wales

7. Sole Voting Power

2,771,374

8. Shared Voting Power

Number of Shares
Beneficially
Owned by
Each Reporting
Person With:

-0-

9. Sole Dispositive Power

2,771,374

10. Shared Dispositive Power

-0-

11. Aggregate Amount Beneficially Owned by Each
Reporting Person

2,771,374 (1)

12. Check if the Aggregate Amount in Row (11)
Excludes Certain Shares

13. Percent of Class Represented by Amount in Row
(11)

6.5% (2)

14. Type of Reporting Person

CO

Footnotes:

(1) Shares of Common Stock held of record by GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of the Reporting Person, issued as of November 30, 2010.

(2) Based on 42,897,186 shares of Common Stock as of October 30, 2014.

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 3

ITEM 1. SECURITY AND ISSUER

This Amendment No. 2 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on December 10, 2010 (as amended by Amendment No. 1 filed on March 1, 2013, the “Schedule 13D” and as amended by this Amendment No. 2, the “Statement”), with respect to the shares of common stock, par value \$0.001 per share (the “Common Stock”), of Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 1020 East Meadow Circle, Palo Alto, CA 94303-4230. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

ITEM 2. IDENTITY AND BACKGROUND

The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 as attached to Amendment No. 1 in its entirety, and replacing it with Schedule 1 attached hereto.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

The response set forth in Item 5 of the Schedule 13D is hereby amended by deleting the previous response in its entirety and

replacing it with the following:

(a) GlaxoSmithKline plc beneficially owns 2,771,374 shares of Common Stock, issued as of November 30, 2010, which represents 6.5% of the 42,897,186 shares of Common Stock outstanding as of October 30, 2014.

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 4

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2015

GLAXOSMITHKLINE PLC

/s/ Victoria A. Whyte

By: Victoria A. Whyte

Title: Company Secretary

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 5

Schedule I

| Name | Business Address | Principal Occupation or Employment | Citizenship |
|----------------------------|---|--|---------------------------|
| Board of Directors | | | |
| Sir Andrew Witty | 980 Great West Road Brentford Middlesex, England TW8 9GS | Executive Director and Chief Executive Officer | British |
| Simon Dingemans | 980 Great West Road Brentford Middlesex, England TW8 9GS 709 Swedeland Road | Executive Director and Chief Financial Officer | British |
| Dr. Moncef Slaoui | King of Prussia Pennsylvania | Executive Director and Chairman Global Vaccines | Moroccan, Belgian & US |
| Sir Christopher Gent | 19406 980 Great West Road Brentford Middlesex, England TW8 9GS | Chairman and Company Director | British |
| Sir Philip Hampton | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director | British |
| Professor Sir Roy Anderson | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director | British |
| Dr. Stephanie Burns | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director | US |
| Stacey Cartwright | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director | British |

Edgar Filing: Anacor Pharmaceuticals, Inc. - Form SC 13D/A

| | | | |
|--------------------|---|------------------|---------|
| Judy Lewent | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director | US |
| Sir Deryck Maughan | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director | British |

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 6

| | | |
|---------------------|---|------------------------|
| Dr. Daniel Podolsky | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director US |
| Tom de Swaan | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director Dutch |
| Lynn Elsenhans | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director US |
| Jing Ulrich | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director US |
| Hans Wijers | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director Dutch |
| Urs Rohner | 980 Great West Road Brentford Middlesex, England TW8 9GS | Company Director Swiss |

Corporate Executive Team

| | | | |
|-------------------|---|--|---------|
| Sir Andrew Witty | 980 Great West Road Brentford Middlesex, England TW8 9GS | Executive Director and Chief Executive Officer | British |
| Simon Dingemans | 980 Great West Road Brentford Middlesex, England TW8 9GS | Executive Director and Chief Financial Officer | British |
| Dr. Moncef Slaoui | 709 Swedeland Road | | |

King of Prussia

Executive Director
Chairman Global Vaccines

Moroccan,
Belgian & US

Pennsylvania

19406

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 7

| | | | |
|---------------------|--|---|---------|
| Deirdre Connelly | 5 Crescent Drive, Philadelphia, PA 19112 | President, North America Pharmaceuticals | US |
| Nick Hirons | 980 Great West Road Brentford Middlesex TW8 9GS | Senior Vice President, Global Ethics and Compliance | British |
| Abbas Hussain | 150 Beach Road 22-00 Gateway West 189720 Singapore Five Moore Drive PO Box 13398 | President, Global Pharmaceuticals | British |
| William Louv | Research Triangle Park North Carolina 27709 | Senior Vice President, Core Business Services | US |
| David Redfern | 980 Great West Road Brentford Middlesex, England TW8 9GS | Chief Strategy Officer | British |
| Claire Thomas | 980 Great West Road | Senior Vice President, Human Resources | British |

| | | | |
|-------------------------|---|--|---------|
| | Brentford Middlesex, England TW8 9GS 980 Great West Road | Senior Vice President, Communications and Government Affairs | British |
| Philip Thomson | Brentford Middlesex, England TW8 9GS 5 Crescent Drive | | |
| Daniel Troy | Philadelphia, PA 19112 980 Great West Road | Senior Vice President & General Counsel | US |
| Dr. Patrick Vallance | Brentford Middlesex, England TW8 9GS 980 Great West Road | President, Pharmaceuticals R&D | British |
| Emma Walmsley | Brentford Middlesex, England TW8 9GS 980 Great West Road | President, Consumer Healthcare | British |
| Roger Connor | Brentford Middlesex, England TW8 9GS | President, Global Manufacturing & Supply | Irish |